Rapid proliferation is one of the critical characteristics of breast cancer. However, the underlying regulatory mechanism of breast cancer cell proliferation is largely unclear. The present study indicated that sevoflurane, one of inhalational anesthetics, could significantly suppress breast cancer cell proliferation by arresting cell cycle at G1 phase. Notably, the rescue experiment indicated that miR-203 was upregulated by sevoflurane and mediated the function of sevoflurane on suppressing the breast cancer cell proliferation. The present study indicated the function of the sevoflurane/miR-203 signaling pathway on regulating breast cancer cell proliferation. These results provide mechanistic insight into how the sevoflurane/miR-203 signaling pathway supresses proliferation of breast cancer cells, suggesting the sevoflurane/miR-203 pathway may be a potential target in the treatment of breast cancer.
Breast cancer is one of the leading causes of death in women worldwide. Fast growth is the important character of breast cancer, which makes sure the subsequent metastasize and invasion breast cancer. Golgi related genes GOLPH3 has been reported to regulate many kinds of cancers proliferation. However, its upregulator remains largely unknown. miRNA modulate gene expression by post-transcriptional repression to participate in many signaling pathway of breast cancer cell proliferation. miR-590 has been reported to regulate tumorgenesis and could be regulated by its own target ATF-3. But whether miR-590 can be the modulator of Golgi related genes to regulate the breast cancer proliferation is unclear. We performed the bioinformatics analysis of survival rate and expression differences of patients using the data of The Cancer Genome Atlas (TCGA).Both of MTS and BrdU assays were used for cell proliferation analysis. Cell cycle was detected by flow cytometry .qRT-PCR was used for detecting the cell cycle related gene expression. Student’s t-test or One way anova was used for statistics. We found the upregulation of GOLPH3 in breast cancer samples compared with normal breast tissues, which also was related to the poor prognosis. Overexpression of GOLPH3 significantly promoted proliferation both of MDA-MB-231 cells (ER negative) and MCF-7 cells (ER positive). We further found that miRNA-590-3p could directly target the 3′-UTR of GOLPH3 mRNA to repress its expression. Overexpression of miR-590-3p inhibited the proliferation of MDA-MB-231 and MCF-7 cells. The rescue experiments indicated that overexpression of GOLPH3 significantly resorted the proliferation inhibited by miR-590-3p. We also found that ATF-3 repressed miR-590-3p expression to modulate miR-590/GOLPH3 pathway to regulate breast cancer cells proliferation. This study not only suggests that the ATF-3/miR-590/GOLPH3 signaling pathway is critically involved in the proliferation of breast cancer cells, but provides a novel therapeutic target and new insight base on epigenetic regulation for future breast cancer diagnosis and clinical treatment.
Colorectal cancer (CRC) currently leads to many deaths worldwide. The regulatory mechanism, however, remains largely unclear. In the present study, bioinformatics methods were used to identify genes associated with CRC prognosis and to detect the molecular signals regulating the cell cycle in two CRC cell lines. It was revealed that BNIPL‑2 expression was higher in CRC tissues than in adjacent tissue samples. Upregulation of BNIPL‑2 was correlated with poor prognosis and the adverse malignant stages T and M. BNIPL‑2 was also associated with signaling pathways involved in cancer cell growth. BNIPL‑2 overexpression promoted cell proliferation and increased the proportion of cells in the G2/M phase. Knockdown of BNIPL‑2 inhibited cell proliferation. CD44 was regulated by BNIPL‑2 and promoted cell proliferation. Downregulation of CD44 suppressed cell proliferation and rescued the cell proliferation promoted by BNIPL‑2. Overexpression of CD44 restored the cell proliferation suppressed by BNIPL‑2 knockdown. The present study not only suggested that BNIPL‑2 may be a potential biomarker of CRC but also indicated that BNIPL‑2 regulates CRC cancer proliferation via CD44, which could be a diagnostic and clinical treatment target.
1 July 2023 in Journal of Biomedical Nanotechnology
Background: Internationally, coronary artery bypass grafting (CABG) is acknowledged as the most efficient way to treat coronary heart disease. In the CABG, sevoflurane and propofol are both used. For patients scheduled for an off-pump CABG, the differentially expressed genes (DEGs) in the anaesthetic gas sevoflurane and the intravenous anaesthetic propofol groups were investigated and compared in this study. Methods: First, DEGs were discovered using the Gene Expression Omnibus-retrieved gene expression profile (GSE129562) (GEO). Additionally, GO (Gene Ontology) function and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway enrichment analysis were performed on the DEGs. Thirdly, protein–protein interactions (PPIs) for the DEGs were created. Results: In the anaesthetic gas sevoflurane group, our investigation identified a total of 1710 DEGs, of which 1320 genes were up-regulated and 390 genes were down-regulated. The top three DEGs in the protein–protein network with the highest degrees are JUN, RELA, and HDAC1. In the intravenous anaesthetic propofol group, our investigation identified a total of 195 DEGs, of which 37 genes were up-regulated and 158 genes were down-regulated. The three DEGs with the highest degrees in the protein–protein network are JUN, FOS, and JUND. These DEGs were shown to be enriched in various keywords and pathways in the anaesthetic gas sevoflurane category or in the intravenous anaesthetic propofol group, according to GO enrichment analysis and KEGG enrichment analysis. JUN is the gene that these two groups have in common. However, the DEGs in the most significant module clearly distinguish among these 2 categories. Conclusion: Our findings show that certain DEGs may have an impact on patients scheduled for off-pump CABG in the sevoflurane gas anesthetic group and the propofol intravenous anesthetic group. These findings may aid future research into the molecular processes and biomarkers.